What Eyevensys does

Eyevensys, now operating as PulseSight Therapeutics, is a clinical-stage biotechnology company founded in 2008 and headquartered in Paris, France. The company is developing non-viral gene therapies dedicated to ophthalmology, targeting severe retinal diseases that lead to blindness. Its pipeline centers on age-related macular degeneration (AMD), geographic atrophy (GA), wet AMD, retinitis pigmentosa, and choroideremia. Lead clinical candidates include PST-611 for dry AMD/Geographic Atrophy (currently in Phase I, with positive interim data presented at ARVO 2026 in May 2026) and PST-809 for AMD.

The company's core technology is a proprietary non-viral gene therapy platform purpose-built for ophthalmic delivery, positioning it as a domain specialist distinct from viral-vector gene therapy competitors. This platform is designed to deliver therapeutic genes to ocular tissues to address degenerative retinal conditions with limited current treatment options. The company operates through traditional biotech commercialization pathways — eventual revenue is expected to flow through specialty healthcare channels (treatment centers, specialty pharmacies) post-regulatory approval, with licensing/royalties as the implied revenue model.

Eyevensys/PulseSight is pre-revenue and venture capital-backed, having raised approximately $52 million cumulatively across multiple Series B-tranche rounds between 2015 and 2021, led successively by Pontifax, Boehringer Ingelheim Venture Fund, and Korea Investment Partners. The company has a lean headcount of 11–50 employees and a leadership team with deep ophthalmology and clinical development expertise, including founder Francine Behar-Cohen serving as Chief Innovation Officer. It was recognized in 2025 as one of the "100 Cell and Gene Therapy Leaders to Watch."

Name

Eyevensys

Legal name

PulseSight Therapeutics

Website

https://eyevensys.com

Company type

Private

Founded year

2008

Operating status

Operating

Headcount range

11–50 employees

Short description

PulseSight Therapeutics (formerly Eyevensys) is a clinical-stage biotech developing non-viral gene therapies for ophthalmology, targeting age-related macular degeneration, geographic atrophy, retinitis pigmentosa, and choroideremia. Its pipeline includes PST-611 and PST-809.

Ownership category

akta.pro rank

Product category

Ophthalmic Gene Therapy Biopharmaceuticals

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Ophthalmology Gene Therapies (HLAAACAG)

akta.pro secondary industries

Rare Ophthalmology Disorder Therapies (HLAIAIAK), Ophthalmology Specialty Pharmaceuticals (HLAIACAK)

Keywords

• Ophthalmic gene therapy
• Non-viral gene delivery
• Retinal disease therapeutics
• Age-related macular degeneration
• Geographic atrophy treatment

Headquarters

HQ city

Paris

HQ country

France

HQ region

Europe

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

1. Gene Therapy Pipeline: Pre-commercial biotech company developing gene therapy treatments for ophthalmology. Revenue model will likely involve pharmaceutical/biotech commercialization through healthcare channels upon regulatory approval.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Core offering

Eyevensys (operating as PulseSight Therapeutics) is a clinical-stage biotechnology company developing non-viral gene therapies dedicated to ophthalmology. Its core offerings are investigational gene therapy product candidates — PST-611 for dry AMD/geographic atrophy and PST-809 for wet AMD — designed to treat severe retinal diseases leading to blindness through a proprietary non-viral gene delivery platform.

Product overview

Eyevensys is a biotechnology company developing gene therapies for eye diseases. The company is focused on developing non-viral gene therapy solutions targeting age-related macular degeneration (AMD), geographic atrophy, and retinitis pigmentosa. Specific named products or therapeutic candidates have not been disclosed in the available source data.

Differentiator

Problem solved

Functional benefit

Brands

• PST-611: Gene therapy product for dry AMD/Geographic Atrophy in clinical development
• PST-809

Products and services

• PST-611 Investigational non-viral gene therapy product candidate for patients with dry age-related macular degeneration (dry AMD) and geographic atrophy (GA), severe retinal diseases that lead to blindness. Developed for administration by ophthalmology specialists in clinical settings.
• PST-809 Pipeline-stage investigational gene therapy candidate for age-related macular degeneration (AMD), being developed using Eyevensys/PulseSight's proprietary non-viral gene delivery platform.

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Scale indicators2 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• MeiraGTx: Clinical-stage gene therapy company with ophthalmology programs including treatments for inherited retinal diseases and AMD. Directly comparable as a clinical-stage gene therapy peer in ophthalmology.
• Adverum Biotechnologies: Clinical-stage biotech developing ADVM-022, an AAV-based gene therapy for wet AMD. Competes directly with PulseSight in ophthalmology gene therapy with similar target indications and delivery approach.
• 4D Molecular Therapeutics: Clinical-stage gene therapy company developing 4D-150 for wet AMD and other ophthalmology indications. Direct competitor with proprietary AAV platform targeting the same indications as PulseSight.
• REGENXBIO: Clinical-stage gene therapy company developing AAV-based therapies including RGX-314 for wet AMD. Most direct competitor to PulseSight in ophthalmology gene therapy targeting AMD.
• GenSight Biologics: Clinical-stage biotech developing GS010, a gene therapy for Leber's Hereditary Optic Neuropathy (LHON). Direct peer in ophthalmology gene therapy with similar regulatory and clinical pathway considerations.

Broad incumbents

• Iveric Bio (Astellas): Developed Izervay (avacincaptad pegol), an FDA-approved C5 inhibitor for geographic atrophy. Acquired by Astellas — represents the established standard-of-care competitor in PulseSight's PST-611 GA indication.
• Coherus BioSciences: Biopharmaceutical company with ophthalmology franchise including Cimerli (ranibizumab biosimilar) competing in wet AMD market. Represents competitive commercial pressure on PulseSight's PST-809 wet AMD indication.
• Gyroscope Therapeutics (Novartis): Developed GT005, a gene therapy for geographic atrophy. Acquired by Novartis in 2022 — represents a strategic exit path and validates M&A appetite for ophthalmology gene therapy assets.
• Spark Therapeutics (Roche): Developer and marketer of Luxturna, the first FDA-approved gene therapy for inherited retinal disease. Acquired by Roche, serves as the broad incumbent benchmark for ophthalmology gene therapy commercialization.

Emerging players

• Kiora Pharmaceuticals: Emerging clinical-stage ophthalmology company developing small molecule and gene therapy approaches for retinal diseases including retinitis pigmentosa. Adjacent peer with overlapping indications but different modality.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds5 records

Investors9 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Eyevensys